50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Cross Country Healthcare target raised to $18.61 by Truist

Published 12/05/2024, 02:24 AM
CCRN
-

On Wednesday, Truist Securities updated its outlook on Cross Country Healthcare (NASDAQ:CCRN), raising the price target to $18.61 from the previous $15.00, while maintaining a Hold rating on the stock.

This adjustment follows the announcement that Cross Country Healthcare, which InvestingPro data shows maintains a strong financial health score of GREAT and holds more cash than debt on its balance sheet, has entered into an acquisition agreement with Aya Healthcare, a private company, for $18.61 per share in cash. This offer is notably a roughly 67% premium over the stock's closing price on Tuesday.

Additionally, the analyst remarked on the broader implications of the deal, "More broadly, we think this is an encouraging signal that the largest Healthcare Staffing company in the country (Aya had ~$9B in 2023 revenues) is seemingly confident enough demand declines are leveling off to make a sizeable acquisition.

The analyst from Truist Securities quoted, "Cross Country Healthcare (CCRN, Hold) has agreed to be acquired by Aya Healthcare for $18.61 in cash, representing a ~67% premium to yesterday's close. The transaction is expected to close in 1H25 and we expect shareholders will approve the transaction."

Additionally, the analyst remarked on the broader implications of the deal, "More broadly, we think this is an encouraging signal that the largest Healthcare Staffing company in the country (Aya had ~$9B in 2023 revenues) is seemingly confident enough demand declines are leveling off to make a sizeable acquisition."

In conclusion, Truist Securities has increased its price target for Cross Country Healthcare to align with Aya Healthcare's acquisition bid, while the Hold rating remains unchanged.

In other recent news, Aya Healthcare is set to acquire Cross Country Healthcare in an all-cash transaction valued at approximately $615 million, expanding Aya's coverage to include Cross Country's work in non-clinical settings. The merger, approved by Cross Country's Board of Directors, is expected to offer immediate value to Cross Country stockholders. Upon completion, Cross Country will become a privately held company, transitioning from its strong liquidity position and minimal debt levels.

Meanwhile, Cross Country Healthcare disclosed its Q3 2024 financial results and provided an outlook for Q4 2024. The company's leadership, including President and CEO John Martins and CFO Bill Burns, led the earnings call, discussing both the company's performance and future expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.